Table 1.
Douek et al. [10] | Thill et al. [11] | Rubio et al. [12] | Pinero-Madrona et al. [13] | Ghilli et al. [14] | Houpeau et al. [15] | Nordic study | |
---|---|---|---|---|---|---|---|
A clearly stated aim | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Inclusion of consecutive patientsa | 1 | 1 | 2 | 2 | 2 | 1 | 2 |
Prospective collection of data | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Endpoints appropriate to the aim of the study | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Unbiased assessment of the study endpointb | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Follow-up period appropriate to the aim | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Loss to follow up less than 5 %c | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Prospective calculation of the study size | 2 | 1 | 2 | 1 | 2 | 2 | 2 |
An adequate control group | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Contemporary groups | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Baseline equivalence of groups | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Adequate statistical analyses | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Total | 23 | 22 | 24 | 23 | 24 | 23 | 24 |
Not reported:0, Reported but inadequate:1, Reported and adequate:2
aNo exclusion or details about the reasons for exclusion
bIf not blind, it has to be explained
cIf important for primary endpoint